

Please amend claims 1-3, 5-8, 14 and 16 as follows:

1. (Amended) Recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) [CSF] protein having a sequence shown in Figure 1.

B<sup>1</sup>  
2. (Amended) Human GM-CSF protein having a specific activity of  $1 \times 10^7$  units/mg in the bone marrow assay, a 15-26 kDa molecular weight and a sequence shown in Figure 1.

3. (Amended) Human GM-CSF protein as claimed in claim 2 which is recombinant GM-CSF protein.

4  
C<sup>one</sup> 5. (Amended) Human GM-CSF protein as claimed in any of claims 1-3, wherein said protein comprises thr<sub>100</sub> or ile<sub>100</sub> [which has the amino acid sequence shown for CSF-thr in Fig. 1, or CSF-ile in Fig. 1, or CSF-G in Fig. 1].

B<sup>2</sup>  
C<sup>one</sup> 6. (Amended) [A] Human GM-CSF protein as claimed in any of claims 1-3, wherein said protein has an N-terminus consisting of ala or met-ala [which contains the amino acid sequence as shown in Fig. 1 commencing with Ala·Pro ... or wherein the amino acid sequence commencing Ala·Pro ... is proceeded by a methionine residue].

6.6  
7. (Amended) [A] Human GM-CSF protein according  
C to <sup>one</sup> any of claims 1-3, comprising at least one of the group  
consisting of ser<sub>3</sub>, arg<sub>10</sub>, ile<sub>36</sub>, val<sub>43</sub>, thr<sub>117</sub> and gly<sub>127</sub> [which  
is a CSF protein corresponding in amino acid sequence to a  
naturally occurring CSF, except that one or more amino acids  
has been added, substituted or removed without substantially  
affecting the biological activity of the natural CSF].

B<sup>2</sup>  
Cond.  
7.7  
8. (Amended) [A] Human GM-CSF protein according  
C to <sup>one</sup> any of claims 1-3, which is a CSF protein having the amino  
C acid sequence of a natural CSF except that it is <sup>preceded</sup> ~~preceded~~ by  
a methionine residue.

8.8  
B<sup>3</sup> 14. (Amended) A [pharmaceutical] composition  
C comprising a human GM-CSF according to <sup>one</sup> any of claims 1-3, [or  
CSF according to claim 1 for use in therapy] in a  
pharmaceutically acceptable carrier.

8.9  
B<sup>4</sup> 16. (Amended) A [pharmaceutical] composition  
C comprising a [recombinant] human GM-CSF according to <sup>one</sup> any of  
claims 1-3, prepared [according to the process of claim 12]  
by the steps comprising:  
precipitating the GM-CSF protein with ammonium  
C sulfate to form a pellet containing the <sup>GM-CSF</sup> ~~CSF~~ protein;  
resuspending the pellet in a buffered solution  
at a pH in the range of about 6 to about 8;